IKIlayda Kayir

Ilayda Kayir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilayda Kayir has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stereotactic radiosurgery for pilocytic astrocytoma: A single center retrospective study

    by Sukran Senyurek, Ilayda Kayir, Dogu Cihan Yildirim, Ali Haluk Duzkalir, Mehmet Orbay Askeroglu, Selcuk Peker

    Introduction: Pilocytic astrocytoma (PA) is a WHO grade I glioma with generally favorable outcomes; however, deep or eloquent tumor locations often limit safe gross total resection. Gamma Knife radiosurgery (GKRS) has emerged as a minimally invasive alternative for residual or recurrent disease. Materials and methods: A retrospective review of 88 patients (60 diagnosed in childhood and 28 in adulthood) treated with GKRS between 2008 and 2024 was conducted. Clinical, radiological, and treatment parameters were analyzed. PFS was assessed with Kaplan–Meier analysis, and predictive factors were identified using univariate and multivariate Cox regression models. Results: Median follow-up was 36 months. Pediatric patients showed 5- and 10-year PFS rates of 84.7% and 66.7%, while adults demonstrated 81.7% at both time points. Multivariate analysis identified prior radiotherapy as the only independent predictor of recurrence in the entire cohort, with significant impact also observed in the pediatric subgroup. Cystic/mixed morphology increased recurrence risk in pediatric patients, while no independent predictors were identified in adults. Discussion and conclusion: GKRS provides durable long-term tumor control in both pediatric and adult PA patients. Prior radiotherapy consistently predicts poorer PFS, underscoring its importance in treatment planning. In pediatric patients, tumor morphology also influences outcomes. Despite the retrospective design and cohort heterogeneity, this represents one of the largest single-center GKRS series and supports GKRS as a safe and effective modality for PA management. Prospective studies are needed to refine patient selection and optimize therapeutic strategies.

  • Efficacy of carotid devices for resistant hypertension: a systematic review

    by Ilayda Kayir, Tanaisha Italia, Avi A Gajjar, Aanand Mehta, Shray Patel, Saarang Patel, Olga Ciobanu-Caraus, Rashad Jabarkheel, Oleg Shekhtman, Albert Qize Wu, et al.

    Background: Resistant hypertension (RHT) affects 10–30% of hypertensive patients, posing a significant challenge, as it leads to greater cardiovascular comorbidities and mortality. Baroreceptor-based therapies, targeting the autonomic nervous system, represent a novel approach for managing RHT when conventional treatments fail. Objective: To evaluate the efficacy, safety, and future potential of carotid devices, including Rheos, Barostim Neo, and MobiusHD, in reducing blood pressure (BP) in patients with RHT. Methods: A PRISMA-guided search of PubMed/Medline, Scopus, and Cochrane databases was conducted to identify studies on carotid baroreceptor devices up to August 2024. Studies were screened for original data on device efficacy and safety, excluding case reports, abstracts, and non-English publications. Data on study design, patient characteristics, and outcomes were extracted and analyzed. Results: Sixteen studies covering Rheos (n=8), Barostim Neo (n=5), and MobiusHD (n=3) were included. Rheos demonstrated significant BP reductions in phase II and III trials but was associated with procedural complications due to its bilateral design. Barostim Neo, a second-generation device, showed comparable efficacy, with a lower complication rate and better compatibility with cardiac devices. MobiusHD, a mechanical endovascular implant, significantly reduced BP over 3 years of follow-up but exhibited procedural risks, such as transient ischemic attacks. Conclusion: Carotid devices offer a promising solution for managing RHT, with Barostim Neo emerging as a safer alternative than Rheos. While MobiusHD demonstrates efficacy, further trials are needed to confirm its safety. Additional studies with standardized trial designs and long-term follow-ups will enhance our understanding of the role of carotid-based therapies in hypertension management.